Here is a full structured case analysis:
Case #1 — Community-Acquired Pneumonia (CAP)
1. Diagnosis
Community-acquired pneumonia (CAP), right lower lobe, moderate severity (PSI Class II)
Diagnostic reasoning:
| Finding | Significance |
|---|
| Fever 39.2°C, 3-day history | Acute infectious process |
| Rust-colored sputum | Classic for Streptococcus pneumoniae (pneumococcal pneumonia) |
| Right-sided pleuritic chest pain | Pleural involvement/irritation |
| RR 22/min, SpO₂ 95% | Mild respiratory compromise |
| Crepitations + ↑ tactile fremitus, right lower lobe | Consolidation |
| CXR: right lower lobe infiltrate | Confirms lobar consolidation |
| WBC 14.2 × 10⁹/L, bands 18%, ESR 42 mm/h | Significant bacterial inflammatory response |
| No hospitalization in past 2 weeks | Rules out hospital-acquired pneumonia |
Most likely pathogen: Streptococcus pneumoniae — supported by lobar pattern, rust-colored sputum, acute onset, and age.
Differentials also cover: Mycoplasma pneumoniae, Haemophilus influenzae, Chlamydophila pneumoniae.
2. Severity Assessment
PSI/PORT Class II
PSI Class II = low mortality risk (~0.6%) → eligible for outpatient management.
CURB-65 cross-check:
| Criterion | Patient | Score |
|---|
| Confusion | No | 0 |
| Urea >7 mmol/L | Not reported | 0 (assume normal) |
| RR ≥30/min | RR 22 — No | 0 |
| BP <90/60 | BP 120/80 — No | 0 |
| Age ≥65 | 34 years — No | 0 |
CURB-65 = 0 → outpatient treatment appropriate.
SpO₂ 95% is borderline (normal cutoff ≥95%) — warrants close monitoring but does not mandate hospitalization alone at Class II.
3. Treatment Plan
Setting: Outpatient (ambulatory)
PSI Class II / CURB-65 = 0 → no indication for hospitalization. No penicillin allergy.
This patient's profile:
- Previously healthy, 34 years old
- No chronic cardiopulmonary disease
- No antibiotics in the past 3 months
- No MRSA/Pseudomonas risk factors
- No penicillin allergy
First-line antibiotic options (per Fishman's Pulmonary & Rosen's Emergency Medicine):
Since this patient has no cardiopulmonary comorbidities and no MRSA/Pseudomonas risk factors:
| Option | Regimen | Duration |
|---|
| Preferred | Amoxicillin 1 g PO three times daily | 5–7 days |
| Alternative | Doxycycline 100 mg PO twice daily | 5–7 days |
| Alternative (if macrolide resistance <25%) | Azithromycin 500 mg day 1, then 250 mg days 2–5 | 5 days |
⚠️ Macrolide monotherapy is no longer recommended unless local pneumococcal resistance is <25% — Rosen's Emergency Medicine.
Note on rust-colored sputum: This strongly suggests pneumococcal etiology. Amoxicillin (β-lactam) is the best targeted choice for S. pneumoniae and is the guideline-preferred first-line agent for low-risk outpatient CAP.
Supportive care:
- Antipyretic/analgesic: Continue paracetamol; add ibuprofen for pleuritic pain if no contraindications
- Hydration: Encourage oral fluids
- Activity: Rest; avoid strenuous activity until afebrile
- Supplemental O₂: Not required outpatient (SpO₂ 95% at rest); advise to return if dyspnea worsens
4. Monitoring & Follow-Up
| Timepoint | Action |
|---|
| 24–48 hours | Phone follow-up — check for fever resolution, worsening dyspnea |
| 48–72 hours | Review sputum culture results; de-escalate or adjust antibiotics if needed |
| Day 3–5 | Clinical reassessment — if no improvement, consider hospitalization and broadened coverage |
| 4–6 weeks | Repeat CXR to confirm radiologic resolution (especially important in adults >40 to exclude underlying malignancy) |
Criteria for hospitalization (escalate if any develop):
- RR ≥30/min or SpO₂ drops below 92%
- New confusion
- BP <90/60 mmHg
- No clinical improvement at 72 hours on antibiotics
5. When Sputum Culture Returns (48–72 h)
- If S. pneumoniae confirmed: continue amoxicillin (optimal)
- If atypical pathogen (Mycoplasma, Chlamydophila): switch to doxycycline or azithromycin
- If resistant organism: adjust per sensitivity report
Summary
This is a 34-year-old healthy male with PSI Class II lobar CAP, most likely pneumococcal given rust-colored sputum and lobar consolidation. Outpatient treatment with amoxicillin 1 g TID × 5–7 days is appropriate, with close follow-up at 48–72 hours and repeat CXR at 4–6 weeks. No hospitalization is required at this stage.
— Fishman's Pulmonary Diseases and Disorders, p. 2202–2203; Rosen's Emergency Medicine, p. 977